Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunochemotherapy in Primary Central Nervous System Lymphoma
NCT01458730Phase 2Completed
- Sponsor
- Aarhus University
- Start
- May 2007
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cytarabine, cyclophosphamide, ifosfamide and 4 more in primary central nervous system lymphoma (PCNSL), sponsored by Aarhus University. Primary endpoint: Overall survival. Started May 2007; status: completed.
02
Drugs
rituximabmethotrexatecytarabinecyclophosphamideifosfamide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT01458730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01458730.